Monday, April 16, 2018
Havana.- Cuba's healthcare system favors the administration of the Cimavax EGF vaccine, which was designed against lung cancer cases in advanced stages.
In 24 hospitals and more than 100 polyclinics nationwide, the drug is administered as part of the basic medication chart of country.
Clinical trials are expected to conclude by the end of this year on about 500 patients, who benefited from the vaccine developed at the Molecular Immunology Center.
The aforementioned formula is considered the first of its kind in the world to control the progression of lung cancer.
Patients are subjected to a vaccination scheme that prevents displacement over long distances, since they receive a first dose in hospitals and the rest in polyclinics.